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patients with newly diagnosed CML in chronic phase. The 
patients were stratified into the following 4 groups based 
on age: young (18–39 years), middle age (40–59 years), 
elderly (60–74 years), and old (≥75 years). The primary 
end point was the rate of molecular response 4  ([MR4] 
BCR–ABL1 ≤0.01% on the international scale) at 18 
months from the initiation of nilotinib.
Results Of the 1091 patients enrolled, 1089 were con-
sidered in the analysis, of whom, 23% (n = 243), 45% 
(n = 494), 27% (n = 300), and 5% (n = 52) were categorized 
as young, middle age, elderly, and old, respectively. At 18 
months, the rates of  MR4 were 33.9% (95% confidence 
Abstract 
Purpose Achievement of deep molecular response with a 
tyrosine kinase inhibitor in patients with chronic myeloid 
leukemia (CML) is required to attempt discontinuation of 
therapy in these patients. The current subanalysis from the 
Evaluating Nilotinib Efficacy and Safety in Clinical Tri-
als as First-Line Treatment (ENEST1st) study evaluated 
whether age has an impact on the achievement of deeper 
molecular responses or safety with frontline nilotinib in 
patients with CML.
Methods ENEST1st is an open-label, multicenter, single-
arm, prospective study of nilotinib 300 mg twice daily in 
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interval [CI], 27.8–40.0%) in the young, 39.6% (95% CI, 
35.3–44.0%) in the middle-aged, 40.5% (95% CI, 34.8–
46.1%) in the elderly, and 35.4% (95% CI, 21.9–48.9%) in 
the old patients. Although the incidence of adverse events 
was slightly different, no new specific safety signals were 
observed across the 4 age groups.
Conclusions This subanalysis of the ENEST1st study 
showed that age did not have a relevant impact on the 
deep molecular response rates associated with nilotinib 
therapy in newly diagnosed patients with CML and eventu-
ally on the eligibility of the patients to attempt treatment 
discontinuation.
Keywords Chronic myeloid leukemia · Nilotinib · 
Frontline · Impact of age · Clinical trial · Molecular 
response
Introduction
Old age was considered as a negative prognostic factor for 
the treatment of chronic myeloid leukemia (CML) and pre-
dicted poor survival outcomes with earlier treatment regi-
mens prior to the use of tyrosine kinase inhibitors (TKIs) 
(Kantarjian et  al. 1987; Silver et  al. 1999; Berger et  al. 
2003). With the advent of imatinib, the overall survival 
(OS) of patients with CML improved substantially (Kantar-
jian et al. 2006; Hochhaus et al. 2009). A number of studies 
have evaluated the effect of age with imatinib, which sug-
gested that imatinib was able to nullify the negative effect 
of age on outcomes with CML therapy (Breccia et al. 2012; 
Proetel et al. 2014).
Second-generation TKIs, including nilotinib and 
dasatinib, were developed for the treatment of patients, 
who were resistant to or intolerant of imatinib. Nilotinib 
 (Tasigna®) was first approved for patients with CML, who 
were resistant to or intolerant of imatinib, and subsequently 
for newly diagnosed patients with CML (Tasigna 2015). 
The pivotal study, Evaluating Nilotinib Efficacy and Safety 
in Clinical Trials-Newly Diagnosed Patients (ENESTnd), 
showed higher rates of major molecular response (MMR; 
BCR–ABL1 ≤0.1% on the International Scale [IS]) and 
lower rates of progression with two doses (300 and 
400  mg) of nilotinib compared to imatinib (Hochhaus 
et al. 2016b). Recent data have shown that achievement of 
deeper molecular responses, molecular response 4  ([MR4] 
BCR–ABL1IS ≤0.01%) and molecular response 4.5  ([MR4.5] 
BCR–ABL1IS ≤0.0032%), results in better treatment out-
comes in patients with CML (Falchi et  al. 2013; Etienne 
et  al. 2014; Hehlmann et  al. 2014). Additionally, in stud-
ies investigating treatment-free remission (TFR) in patients 
with CML, the eligibility criteria are the achievement 
of stable deep molecular responses (Hughes et  al. 2016; 
Saglio et  al. 2016). The ENEST1st study was, therefore, 
conducted to evaluate the efficacy of nilotinib in achieving 
deeper molecular responses in a large patient population of 
newly diagnosed patients with CML who were BCR–ABL1 
positive (Hochhaus et al. 2016a). The results from the study 
showed that a majority of the patients achieved  MR4 by 24 
months with progression-free survival (PFS) rate of almost 
100%.
Studies evaluating the impact of age on the safety and 
efficacy of second-generation TKIs, including nilotinib, 
are limited. The limited data available on the effect of age 
only evaluated the response rates for broader categories like 
elderly patients with age greater than 60 or 65 and younger 
patients (le Coutre et  al. 2009; Larson et  al. 2011). The 
current subanalysis of the ENEST1st study evaluated the 
impact of age on the deep molecular response and safety 




The subanalysis included all patients enrolled in the mul-
ticenter ENEST1st study, which recruited patients from 26 
European countries. The inclusion and exclusion criteria 
have been previously published (Hochhaus et  al. 2016a). 
Briefly, male or female patients with Philadelphia chromo-
some (Ph) or BCR–ABL1 + CML in chronic phase (CML-
CP), aged ≥18 years and were within 6 months of diagnosis 
of the disease, were enrolled. Patients were also required 
to have a World Health Organization performance status 
of ≤2. Patients who had prior treatment with hydroxyurea 
(>6 months) or imatinib (>3 months) were not included. 
Patients with ventricular-paced pacemaker, congenital long 
QT syndrome, QTcF >450 ms, myocardial infarction within 
the past 12 months, or other clinically significant heart dis-
ease were excluded. In addition, patients with impaired 
gastrointestinal function, concurrent uncontrolled medical 
conditions that would present unacceptable safety risks or 
compromise compliance with the protocol, or concomitant 
treatment with medications with the potential to prolong 
the QT interval or known to be strong inducers or inhibitors 
of cytochrome P450 3A4 are also excluded. Informed con-
sent was obtained from each patient in writing before any 
study-specific procedures were performed.
Study design and treatment
The ENEST1st was a multicenter, single-arm study 
evaluating nilotinib at 300  mg twice daily (bid) in newly 
diagnosed and previously untreated patients. ENEST1st 
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was registered in the EU Clinical Trials Registry (2009-
017775-19) and ClinicalTrials.gov (NCT01061177). In this 
subanalysis, the patients were stratified to four subgroups 
according to age at the time of study entry. The 4 groups 
that were defined for the purpose of this study were young 
patients (18–39 years), middle-aged patients (40–59 years), 
elderly patients (60–74 years), and old patients (≥75 years). 
The primary end point was the rate of  MR4 at 18 months 
from the initiation of nilotinib. The secondary end points 
included rates of  MR4 and  MR4.5 at various time points, 
OS, and PFS. Safety was evaluated throughout the study, 
and National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 for tox-
icity and adverse event (AE) reporting was used to report 
AEs. All patients were treated with an initial dose of nilo-
tinib 300 mg bid for up to 24 months. Dose escalation was 
not allowed beyond 300  mg bid of nilotinib. Dose reduc-
tions were permitted for grade 3 or 4 hematologic AEs 
related to white blood cells or platelets and for clinically 
significant nonhematological AEs of severity greater than 
grade 2. The study protocol for the ENEST1st study did not 
require regular monitoring of lipid and glucose profiles.
The study protocol was approved by the independent 
ethics committee (IEC) or institutional review board (IRB) 
for each center and was conducted according to the ethical 
principles of the Declaration of Helsinki.
Assessments
The molecular response rates assessed by the BCR–ABL1 
transcript levels determined by multiplex polymerase 
chain reaction (PCR) at baseline and subsequently every 
3 months by real-time quantitative PCR at a designated 
European Treatment Outcome Study (EUTOS) laboratory 
standardized to IS. Samples with a total of <10,000 ABL1 
transcripts or <32,000 ABL1 transcripts were considered as 
not evaluable for  MR4 or  MR4.5, respectively. In the study, 
PFS was defined as the time from start of the study drug to 
the earliest progression to accelerated phase or blast crisis 
(AP/BC) or death from any cause, and OS was defined as 
the time from the start of the study drug to death from any 
cause.
Statistical analyses
The intention-to-treat (ITT) population and the safety sets 
consisted of all patients who received at least one dose of 
study drug and was used for demographics, baseline char-
acteristics, efficacy analyses, and safety. For the evaluation 
of the molecular response, only those patients in the ITT 
population with typical BCR–ABL1 transcripts at screen-
ing, i.e., b3a2 and/or b2a2, were considered. For calcula-
tion of response rates “at” a designated time point, patients 
were considered responders only if an assessment at that 
time point showed achievement of the response. Response 
rates “by” a designated time point were calculated as cumu-
lative response rates, counting all patients with a response 
detected at or before the specified time point as respond-
ers. All response rates were calculated as raw proportions. 
Rates of freedom from progression to AP/BC on treatment 
and OS were estimated using Kaplan–Meier product limit 
estimates according to ITT principles.
Results
Patients
In the ENEST1st study, from 2010 to 2012, 1164 patients 
were screened and 1091 patients were enrolled across 
26 European countries in 307 sites (Fig.  1). Of the 1091 
patients, 1089 patients who received ≥1 dose of nilotinib 
300  mg bid were considered in the ITT analysis. Of the 
1089 patients, 23% (n = 243), 45% (n = 494), 27% (n = 300), 
and 5% (n = 52) were categorized as young, middle age, 
elderly, and old, respectively, according to the defined crite-
ria. Overall, the median age of the population was 53 years 
(range 18–91 years) and 59% were male. Except for the 
group with old patients, all groups had more males com-
pared to females (Table  1). The young, middle-aged, and 
the elderly groups, respectively, had 34.6, 42.1, and 42.7% 
of female patients compared to 51.9% of females in the old 
group. Overall, the median time since diagnosis for the 
patients was 0.9 months (range <0.1–6.6 months) and was 
similar when evaluated by age group (Table 1). According 
to the Sokal risk score, overall, 377 patients (34.6%) were 
categorized as low risk, 408 (37.5%) as intermediate risk, 
and 197 (18.1%) as high risk; Sokal risk score could not 
be calculated for 107 patients (9.8%) due to missing infor-
mation. More than 80% of patients (n = 900, 82.6%) were 
considered to be at low risk based on the EUTOS score 
and 8.6% (n = 94) at high risk, and information was miss-
ing for 8.7% (n = 95). In each of the age category, most of 
the patients were at low or intermediate risk based on the 
Sokal risk score and low risk based on the EUTOS risk 
score (Table  1). Based on the Sokal risk score, none of 
the patients in the old group were at low risk, while about 
half of the patients in the young (55.6%) and the middle 
age groups (41.1%) were at low risk. More than half of 
the patients in the elderly (53.0%) and in the old (69.2%) 
groups were at intermediate risk for Sokal score. Based 
on the EUTOS risk score, a slightly higher percentage 
of patients were at high risk in young age group (12.8%) 
compared to the other age categories. The percentages of 
eosinophils, basophils, and platelets were similar across the 
age groups, but the percentage of blasts was slightly higher, 
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and the spleen size was comparatively bigger in the young 
patients than in the other age groups.
Of the 1089 patients enrolled, 881 (80.9%) completed 
24 months of study treatment and 208 (19.1%) discontin-
ued. Discontinuation rates were 16.9% in young patients, 
16.2% in middle-aged patients, 22.3% in elderly, and 
38.5% in old patients, which was the highest among the 
four age groups (Fig. 1). Across all age groups, the most 
common reason for discontinuation was AEs, accounting 
for 36.6, 61.2, 61.2, and 60% of all discontinuations in 
the young, middle-aged, elderly, and old patients, respec-
tively. On the other hand, of the patients discontinued, 
17.1, 8.1, 4.5%, and none discontinued due to disease 
Screening failure (n = 73)
Reason for exclusion:
• Typical BCR-ABL1 transcripts not detected at baseline (n = 33)a
• Received > 3 months imatinib therapy prior to enrollment (protocol violation; n = 4)
Enrolled (n = 1091)
Screened (n = 1164)
ITT/safety population (N = 1089)
Molecular analysis population (n = 1052)
Reason for exclusion:
• Did not receive ≥ 1 dose of study drug (n = 2)
Young patients
(n = 243; 23%)
Middle-age patients
(n = 494; 45%)
Elderly patients
(n = 300; 27%)
Old patients
(n = 52; 5%)
Treated (n = 243)
Discontinued 
(n = 41; 16.9%)







• Lost to follow-up
(n = 4)
• Abnormal laboratory 
value (n = 1)
• Abnormal test result
(n = 1)
• Administrative 
problems (n  = 1)
Treated (n = 494)
Discontinued 
(n = 80; 16.2%)
• AEs (n = 49)
• Consent withdrawal 
(n = 7)
• Disease progression 
(n = 7)c
• New cancer therapy 
(n = 5)
• Abnormal laboratory 
value (n = 3)




• Abnormal test result 
(n = 2)
• Administrative 
problems (n = 2)
• Death (n = 1)
Treated (n = 300)
Discontinued 
(n= 67; 22.3%)
• AEs (n = 41)




• New cancer therapy 
(n = 4)
• Disease progression 
(n = 3)
• Lost to follow-up 
(n = 3)
• Death (n = 2)
• Abnormal test result 
(n = 1)
Treated (n = 52)
Discontinued 
(n= 20; 38.5%)
• AEs (n = 12)
• Abnormal laboratory 
value (n = 2)
• Consent withdrawal 
(n = 3)
• Protocol deviation 
(n = 1)
• Administrative 
problems (n  = 1)









Fig. 1  Patient disposition. aPatients not in the molecular analysis 
population were distributed in the age groups as follows: 9 patients 
in young, 18–39 years old, 10 patients in middle-aged, 40–59 years 
old, 10 patients in elderly, 60–74 years old, 4 patients in old, ≥75 
years old, groups; btwo patients in the young group who discontinued 
due to progression to AP/BC are considered under disease progres-
sion; cfour patients in the middle-aged group who discontinued due to 
progression to AP/BC are considered under disease progression. ITT 
intention–to-treat, Ph philadelphia chromosome
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progression or treatment failure in the young, middle-
aged, elderly, and old age groups, respectively.
The overall median (range) duration of exposure was 
722 days (5–821 days) and did not vary much across the 
four age groups studied (Table 2). The median dose inten-
sity was around 600  mg/day across all groups. A total of 
492 patients (45.2%) underwent dose change or inter-
ruptions. Dose reductions were comparatively less in old 
patients, while dose interruptions were more frequent in 
this group compared to the other groups (Table 2).
Molecular response rates
Among the 1082 patients, 1052 were considered for the 
evaluation of the molecular response rates. Overall, the 
rate of  MR4 at 18 months was 38.4% (95% CI, 35.5–41.3%; 
n = 404). At 18 months, the rates of  MR4 were 33.9% (95% 
CI, 27.8–40.0%) in the young adult patients, 39.6% (95% 
CI, 35.3–44.0%) in the middle-aged patients, 40.5% (95% 
CI, 34.8–46.1%) in the elderly patients, and 35.4% (95% CI, 
21.9–48.9%) in the old patients (Fig. 2a). The rates of  MR4.5 
at 18 months were 18% (95% CI, 13.1–23.0%), 22.4% (95% 
CI, 18.7–26.1%), 21.8% (95% CI, 17.0–26.6%), and 14.6% 
(95% CI, 4.6–24.6%) in the young adults, middle-aged, 
elderly, and old patients, respectively. The  MR4 and  MR4.5 
rates at 6, 12, and 24 months are presented in Fig. 2. In the 
overall population, cumulative rates of  MR4 and  MR4.5 
by 24 months were 55.2% (n = 581) and 38.6% (n = 406), 
respectively. By 24 months, the rates of  MR4 among 
patients were 50.2% (95% CI, 43.8–56.6%; n = 117) in the 
Table 1  Baseline demographics
CML chronic myeloid leukemia, EUTOS European Treatment Outcome Study
Characteristics Young  
(18–39 years)
(n = 243)









Median age (range), years 32 (18–39) 50 (40–59) 66 (60–74) 78 (75–91)
Male/female (%) 159/84 (34.6%) 286/208 (42.1%) 172/128 (42.7%) 25/27 (51.9%)
Time since initial diagnosis 
of CML (months); median 
(range)
0.86 (0.07, 5.86) 0.92 (0.07, 6.61) 0.92 (0.03, 60.99) 0.86 (0.07, 6.02)
Sokal score, n (%)
 High risk 31 (12.8) 84 (17.0) 71 (23.7) 11 (21.2)
 Intermediate risk 52 (21.4) 161 (32.6) 159 (53.0) 36 (69.2)
 Low risk 135 (55.6) 203 (41.1) 39 (13.0) –
 Missing 25 (10.3) 46 (9.3) 31 (10.3) 5 (9.6)
EUTOS score, n (%)
 High risk 31 (12.8) 39 (7.9) 22 (7.3) 2 (3.8)
 Low risk 190 (78.2) 412 (83.4) 252 (84.0) 46 (88.5)
 Missing 22 (9.1) 43 (8.7) 26 (8.7) 4 (7.7)
Laboratory parameters
 Peripheral blasts %, 
mean ± SD (n)
2.05 ± 3.03 (230) 1.60 ± 2.33 (475) 1.49 ± 2.25 (283) 0.98 ± 1.04 (48)
 Peripheral eosinophils %, 
mean ± SD (n)
2.88 ± 3.37 (234) 2.73 ± 2.64 (479) 2.85 ± 3.14 (289) 2.47 ± 2.37 (49)
 Peripheral basophils %, 
mean ± SD (n)
4.02 ± 3.75 (234) 4.07 ± 3.83 (478) 4.08 ± 3.95 (292) 3.89 ± 3.72 (50)
 Platelets  (109/L), mean ± SD 
(n)
446.47 ± 312.07 (240) 464.08 ± 352.63 (487) 463.28 ± 308.61 (297) 423.69 ± 233.39 (51)
 Spleen size, cm 5.01 ± 6.19 (226) 3.22 ± 4.90 (461) 2.46 ± 4.13 (276) 1.53 ± 3.06 (49)
Previous CML therapy, n (%)
 Imatinib ≤1 month 17 (7) 32 (6.5) 16 (5.3) 2 (3.8)
 Imatinib >1–2 months 13 (5.3) 33 (6.7) 24 (8.0) 1 (1.9)
 Imatinib >2–3 months 16 (6.6) 20 (4) 10 (3.3) 4 (7.7)
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Table 2  Drug exposure
Young (n = 243) Middle age (n = 494) Elderly (n = 300) Old (n = 52)
Duration of exposure, days (median, range) 722.00 (46–821) 724 (5–793) 724 (1–798) 709 (4–780)
Time of treatment, days (median, range) 728 (46–960) 728 (5–888) 728 (1–817) 718 (4–780)
Average daily dose, mg/day, (mean ± SD) 583.1 ± 50.7 587.0 ± 46.4 577.6 ± 66.4 576.5 ± 64.9
Dose intensity, mg/day (median, range) 600 (257.8–620.5) 600 (144.4–689.0) 600 (173.9–625.7) 598.5 (300.0–600.0)
Dose reductions, n (%) 71 (29.2%) 146 (29.6%) 90 (30.0%) 14 (26.9%)
 1 Dose reduction 32 (13.2) 76 (15.4) 46 (15.3) 6 (11.5)
 2 Dose reductions 15 (6.2) 30 (6.1) 20 (6.7) 5 (9.6)
 >2 Dose reductions 24 (9.9) 40 (8.1) 24 (8) 3 (5.8)
Dose interruptions, n (%) 84 (34.6%) 168 (34.0%) 113 (37.7%) 22 (42.3%)
 1 Dose interruption 39 (16.1) 95 (19.2) 57 (19.0) 14 (26.9)
 2 Dose interruptions 20 (8.2) 44 (8.9) 21 (7.0) 4 (7.7)
 >2 Dose interruptions 25 (10.3) 29 (5.9) 35 (11.7) 4 (7.7)
Fig. 2  Molecular response 
rates in the molecular analy-
sis population (n = 1052). a 
Rates of  MR4 at 6, 12, 18, 
and 24 months by age group. 
MR4 molecular response 4 
 (MR4; BCR–ABL1IS ≤0.01), 
IS international scale. b Rates 
of  MR4.5 at 6, 12, 18, and 24 
months by age group. MR4.5 
molecular response 4.5  (MR4.5; 
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6 months 12 months 18 months 24 months
A
B
Young (n = 233) Middle-age (n = 482) Elderly (n = 289) Old (n = 48)
Young (n = 233) Middle-age (n = 482) Elderly (n = 289) Old (n = 48)
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young age group, 57.1% (95% CI, 52.6–61.5%; n = 275) in 
the middle-aged group, and 57.4% (95% CI, 51.7–63.1%; 
n = 166) and 47.9% (95% CI, 33.8–62.0%; n = 23) in the 
elderly and the old patients, respectively. The rates of  MR4.5 
in the young adults, middle-aged, elderly, and old patients 
were 35.6% (95% CI, 29.5–41.8%; n = 83), 39.4% (95% 
CI, 35.1–43.8%; n = 190), 39.8% (95% CI, 34.1–45.4%; 
n = 115), and 37.5% (95% CI, 23.8–51.2%; n = 18) by 24 
months, respectively. The rates of  MR4 based on the Sokal 
risk score are presented in Table  3. Similar rates of  MR4 
were seen across the age groups, except for the young adult 
patients with intermediate risk and old patients with high 
risk, which showed considerably lower rates of  MR4; 14 of 
49 patients (28.6%) in the young group with intermediate 
risk and 2 of 10 patients (20.0%) in the old group with high 
risk achieved  MR4.
Overall survival and progression‑free survival
Overall, for the patients included in the ITT set, the esti-
mated OS at 12 months was 99.6% (95% CI, 99.0–99.9%) 
and at 24 months was 98.9% (95% CI, 98.0–99.4%). There 
were 18 deaths reported in this study, of which 14 occurred 
more than 28 days after the last dose of the study drug. The 
four deaths occurring within 28 days of the last dose of the 
study drug or the 24-month evaluation included death due 
to pulmonary embolism, aortic valve stenosis, thrombo-
cytopenia, and pneumonia (one patient each). None of the 
four deaths were suspected to be related to the study drug. 
The 14 deaths occurring after 28 days of the last dose of the 
study drug or the 24-month evaluation included death due 
to secondary cancer (three patients), sepsis (two patients), 
unknown cause (two patients), progression of CML, pneu-
monia, cardiac failure, cerebral infarction, ischemic stroke, 
complications during a stem cell transplant, and suicide 
(one patient, each).
Overall, there were six progression events, three patients 
each on treatment progressed to AP and BC, though none 
of them died on the study. Of the six events, two were 
observed in the young group and four in the middle-aged 
group. By 24 months, the estimated rate of freedom from 
progression to AP/BC on treatment was 99.1% (95% 
CI, 97.7–99.7%) in middle-aged and 99.2% (95% CI, 
96.6–99.8%) in young patients, while it was 100% in both 
the elderly and old patients.
Adverse events
The overall safety results of the ENEST1st study are pre-
sented in Hochhaus et  al. (2016a). The most common 
nonhematological AEs included rash, pruritus, headache, 
abdominal pain, fatigue, nausea, alopecia, and nasophar-
yngitis (Hochhaus et al. 2016a). Although the incidence of 
AEs was slightly different, no new specific safety signals 
were observed across the four age groups (Table  4). The 
most frequent nonhematological AEs were rash in young 
(21.4%) and the middle-aged (24.9%), and pruritus (18.3%) 
and nausea (19.2%) in elderly and old patients, respec-
tively. Among hematological AEs, thrombocytopenia was 
the most frequent AE that was observed in young (14.8%), 
middle-aged (9.3%), and elderly patients (9.3%), while in 
old patients anemia (15.4%) was the more common hema-
tological AE (Table 5). The common biochemical labora-
tory abnormalities included increase in bilirubin, increase 
in alanine aminotransferase (ALT), decrease in phosphate, 
increase in lipase, and arterial hypertension (Table  6). 
Among the age groups, arterial hypertension was less fre-
quent in young patients (2.9%) compared to the other age 
groups (middle-aged, 6.3%; elderly, 7.3%; old, 9.6%); while 
increases in bilirubin, ALT, and aspartate aminotransferase 
(AST) were less frequent or absent in the old population. 
Frequency of grade 3 or 4 abnormalities was relatively less 
for nonhematological AEs compared to the hematological 
AEs. Of the total incidence of thrombocytopenia and neu-
tropenia, more than 50% were of grade 3 or 4 except in the 
old patients, in whom it was only 1.9%. Overall, the inci-
dence of grade 3 or 4 AEs was less frequent in old patients.
The cardiovascular AEs by age group are presented in 
Table 7. By Fisher’s exact test, there was a significant dif-
ference (P ≤0.0001) in the incidence of cardiovascular 
events (CVEs) overall, across the age groups, with very 
low incidence in the young patients compared to the other 
age groups (Table 7). Among the CVEs, the incidence of 
ischemic heart disease was significantly different across 
age groups (P <0.0002), while peripheral arterial occlusive 
disease and ischemic cerebrovascular event did not differ 
significantly across age groups. It was not mandatory to 
Table 3  Effect of Sokal risk on 
the  MR4 by age group
MR4 molecular response 4 (BCR–ABL1IS ≤0.01%), IS international scale
MR4 by 24 months by Sokal 
risk group, %
Young (n = 233) Middle age 
(n = 482)
Elderly (n = 289) Old (n = 48)
Low 56.9 62.3 63.2 –
Intermediate 28.6 54.1 58.4 51.5
High 44.8 46.4 54.4 20.3
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Table 4  Most frequent all grades (≥10% in any group) nonhematological adverse events (AEs)
AEs Young (n = 243), n (%) Middle age (n = 494), n (%) Elderly (n = 300), n (%) Old (n = 52), n (%)
All grades Grade 3 or 4 All grades Grade 3 or 4 All grades Grade 3 or 4 All grades Grade 3 or 4
Abdominal pain 33 (13.6) 1 (0.4) 74 (15.0) 5 (1.0) 45 (15.0) 2 (0.7) 8 (15.4) –
Rash 52 (21.4) 1 (0.4) 123 (24.9) 1 (0.2) 52 (17.3) 1 (0.3) 6 (11.5) –
Pruritus 33 (13.6) 1 (0.4) 83 (16.8) 1 (0.2) 55 (18.3) 1 (0.3) 9 (17.3) –
Fatigue 31 (12.8) 1 (0.4) 76 (15.4) 4 (0.8) 41 (13.7) 1 (0.3) 3 (5.8) –
Headache 51 (21.0) 5 (2.1) 86 (17.4) 3 (0.6) 25 (8.3) – 4 (7.7) –
Nausea 19 (7.8) 2 (0.8) 59 (11.9) – 35 (11.7) 3 (1.0) 10 (19.2) –
Nasopharyngitis 36 (14.8) – 44 (8.9) – 31 (10.3) – 2 (3.8) –
Alopecia 25 (10.3) 1 (0.4) 59 (11.9) – 24 (8.0) – 7 (13.5) –
Dry skin 17 (7.0) – 43 (8.7) – 30 (10.0) – 3 (5.8) –
Myalgia 26 (10.7) 1 (0.4) 52 (10.5) – 19 (6.3) 1 (0.3) 2 (3.8) –
Muscle spasm 13 (5.3) – 48 (9.7) – 30 (10.0) – 2 (3.8) –
Diarrhea 16 (6.6) - 39 (7.9) 1 (0.2) 35 (11.7) 1 (0.3) 4 (7.7) –
Table 5  Most frequent hematologic adverse events (AEs) (≥5% in any group) of interest
AEs Young, n (%) Middle age, n (%) Elderly, n (%) Old, n (%)
All grades Grade 3–4 All grades Grade 3–4 All grades Grade 3–4 All grades Grade 3–4
Thrombocytopenia 36 (14.8) 20 (8.2) 46 (9.3) 28 (5.6) 28 (9.3) 17 (5.7) 3 (5.8) 1 (1.9)
Anemia 13 (5.3) 4 (1.6) 28 (5.7) 5 (1.0) 18 (6.0) 7 (2.3) 8 (15.4) 1 (1.9)
Neutropenia 14 (5.8) 12 (4.9) 20 (4.0) 11 (2.2) 7 (2.3) 6 (2.0) 2 (3.8) 1 (1.9)
Leukopenia 7 (2.9) 1 (0.4) 13 (2.6) 4 (0.8) 5 (1.7) 3 (1.0) – –
Lymphopenia 2 (0.8) – 1 (0.2) – 1 (0.3) – – –
Table 6  Most frequent (≥5% in any group) laboratory abnormalities
ALT alanine aminotransferase, AST aspartate aminotransferase
Laboratory abnormalities Young, n (%) Middle age, n (%) Elderly, n (%) Old, n (%)
All grade Grade 3 or 4 All grade Grade 3 or 4 All grade Grade 3 or 4 All grade Grade 3 or 4
Total bilirubin ↑ 25 (10.3) 5 (2.1) 36 (7.3) 5 (1.0) 17 (5.7) 4 (1.3) 2 (3.8)
ALT ↑ 27 (11.1) 4 (1.6) 49 (9.9) 9 (1.8) 9 (3.0) 2 (0.7) 1 (1.9) 1 (1.9)
AST ↑ 14 (5.8) 1 (0.4) 26 (5.3) 4 (0.8) 11 (3.7) 1 (0.3) –
Phosphate ↓ 13 (5.3) 6 (2.5) 48 (9.7) 15 (3.0) 15 (5.0) 3 (1.0) 1 (1.9)
Lipase ↑ 7 (2.9) 3 (1.2) 37 (7.5) 16 (3.2) 30 (10) 18 (6.0) 3 (5.8) 1 (1.9)
Hypertension 7 (2.9) 31 (6.3) 4 (0.8) 22 (7.3) 6 (2.0) 5 (9.6) 2 (3.8)
Table 7  Cardiovascular adverse events (AEs) by age group
*P values provided are nominal, post hoc, and for descriptive purpose only; no multiplicity adjustments were made
Cardiovascular AEs Young (n = 243) Adult (n = 494) Elderly (n = 300) Old (n = 52) P value by 
Fisher’s exact 
test*
Cardiovascular events 2 (0.8%) 26 (5.3%) 30 (10%) 7 (13.5%) <0.0001
Ischemic heart disease 1 (0.4%) 14 (2.8%) 17 (5.7%) 5 (9.6%) 0.0002
Peripheral arterial occlusive disease 1 (0.4%) 9 (1.8%) 9 (3.0%) 1 (1.9%) 0.12
Ischemic cerebrovascular event 0 4 (0.8%) 4 (1.3%) 1 (1.9%) 0.19
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monitor the lipid profile and glucose routinely as per the 
protocol. However, AEs related to hypercholesterolemia 
(3.0%), hyperglycemia (3.3%), and diabetes mellitus (1.2%) 
were reported earlier for the overall population (Hochhaus 
et al. 2016a).
Discussion
The ENEST1st study evaluated deep molecular response 
with nilotinib in newly diagnosed patients with CML 
(Hochhaus et al. 2016a). This subanalysis of the ENEST1st 
study was conducted to assess the impact of age on deep 
molecular response and AEs with frontline nilotinib. The 
ENEST1st study had shown that among the patients ana-
lyzed for molecular response, 38.4% achieved  MR4 at 18 
months and 55.2% achieved  MR4 by 24 months. When cat-
egorized into 4 age groups comprising young, middle age, 
elderly, and old patients, molecular response rates across 
the groups were consistent with the overall population. To 
the best of our knowledge, this subanalysis is the first to 
compare the safety and efficacy of frontline nilotinib across 
the four different age groups.
In the earlier studies with busulfan, hydroxyurea, and 
allogeneic stem cell transplantation, older age was con-
sidered to negatively impact the response and survival 
outcomes (Silver et al. 1999; Berger et al. 2003) and indi-
cated poor prognosis in patients with CML (Kantarjian 
et  al. 1987). However, later studies evaluating the impact 
of age on response rates with imatinib have been conflict-
ing. In a study by Rosti et al., in patients with CML in late 
CP, lower rates of complete hematologic response (CHR) 
and complete cytogenetic response (CCyR) were observed 
in patients >65 years compared to younger patients, though 
OS was the same (Rosti et  al. 2007). Gugliotta et  al. in 
2011, however, suggested no impact of age on the response 
rates upon treatment with imatinib (Gugliotta et al. 2011). 
However, it should be noted that there was a slight differ-
ence in the disease stage of the patients in the two stud-
ies. The first  study included patients in late chronic 
phase who were resistant to interferon alpha, treated with 
imatinib, while the second study included patients in early 
chronic phase treated with frontline imatinib. Earlier in a 
large study of more than 700 patients at the MD Anderson 
center, no differences in the CCyR and OS were observed 
between patients over 60 years and younger patients (Cor-
tes et al. 2003).
A few studies have evaluated the impact of age on the 
safety and efficacy of second-generation TKIs in elderly. In 
the phase 2 study, in imatinib-resistant/intolerant patients 
who were treated with nilotinib, more patients <65 years of 
age achieved major cytogenetic response (MCyR; 63%) and 
CCyR (44%), compared with patients ≥65 years (MCyR, 
48%; CCyR, 38%) (Lipton et  al. 2008). The estimated 
OS rates at 12 months were higher for patients <65 years 
(97%) compared with patients ≥65 years (91%) (Lipton 
et al. 2008; le Coutre et al. 2009). However, in the ENACT 
study, which evaluated the response rates for patients ≥60 
years, rate of CHR was comparable to that of the overall 
population (le Coutre et  al. 2009). In the pivotal phase 3 
ENESTnd study, MMR rates by 24 months for patients 
aged ≥65 years and those <65 years were similar for those 
treated with 300  mg but was slightly lower for the older 
patients (61%) on 400  mg of nilotinib bid, compared to 
younger patients (67%) (Larson et al. 2011). A subanalysis 
in the pivotal DASISION trial, which compared frontline 
imatinib with dasatinib, was one of the very few trials that 
compared the response rates in three different age groups 
comprising patients <46 years, patients aged between 46 
years and 55 years, and those aged >65 years (Khoury et al. 
2010). The response rates did not vary substantially with 
CCyR rates in the three groups ranging between 78 and 
88% and MMR rates from 45 to 50%.
A number of studies have demonstrated that deep molec-
ular response with TKIs resulted in better outcomes in 
patients with CML (Falchi et al. 2013). In the ENESTcmr 
study, patients who could not achieve molecular response 
with imatinib could achieve it after switching to nilotinib; 
while in the ENESTnd study more patients achieved  MR4 
and  MR4.5 with nilotinib compared to imatinib (Hughes 
et al. 2014; Hochhaus et al. 2016b). The ENEST1st study 
conducted in a large patient population of more than 1000 
patients further confirmed the efficacy of frontline nilotinib 
with a better response than in the ENESTnd study, in which 
39 and 25% achieved  MR4 and  MR4.5 by 24 months, com-
pared to 56 and 38% in the ENEST1st study, respectively 
(Hochhaus et al. 2016a).
Most studies, including the ENESTnd that evaluated 
the impact of age, have categorized patients broadly into 
elderly patients who were older than 60 or 65 years and 
those who were younger. The classification made in this 
analysis, with subgroups ranging from 15 to 20 years each, 
would enable us to identify any differences, which may be 
lost due to a broader classification. The current study did 
not show any major difference between the age groups ana-
lyzed, though comparatively weaker responses were seen 
for younger patients compared to the older patients. The 
younger patients in particular had a higher percentage of 
blasts and spleen size compared to the older patients as has 
also been reported in other studies (Pemmaraju et al. 2012; 
Kalmanti et  al. 2014; Castagnetti et  al. 2015). Somewhat 
similar approach has earlier been seen with the CML IV 
study with >1500 patients and the GIMEMA CML work-
ing group studies with >2500 patients, which were large 
studies and also evaluated the impact of age in patients 
with CML treated with TKIs. In these studies (Kalmanti 
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et al. 2014; Castagnetti et al. 2015), in which the patients 
were classified into 3 to 4 categories of age, as in the cur-
rent study, it was seen that younger patients with CML typ-
ically present with a more expanded disease (Pemmaraju 
et  al. 2012; Kalmanti et  al. 2014; Castagnetti et  al. 2015) 
and a higher incidence of hematologic toxicity as also 
seen here (Pemmaraju et al. 2012). In a study by Kalmanti 
et  al., poor prognostic indicators in younger patients did 
not seem to affect their response to frontline imatinib 
(Kalmanti et al. 2014). However, according to Pemmaraju 
et  al. young adults showed comparatively lower response 
rates to frontline TKIs compared to older patients, though 
transformation-free survival, and the OS remained similar 
(Pemmaraju et al. 2012). Further analysis in this age group 
might be needed. Since the current study enrolled newly 
diagnosed patients according to protocol inclusion and 
exclusion criteria, the elderly and the old patients could 
have been healthier; hence, better efficacy and tolerability 
to some drug- or disease-related AEs were seen compared 
to young adults. The responses could also reflect a possi-
ble selection bias of the investigators in recruiting younger 
patients into the clinical trials compared to population-
based registries as is also reported by other authors (Rohr-
bacher et al. 2009).
Recently, the therapeutic landscape of CML is moving 
toward the goal of achieving TFR, and one of the major 
criteria for patients to attempt to discontinue treatment is 
a sustained molecular response (Hughes and Ross 2016). 
Many studies investigating the predictors of successful 
TFR have also evaluated age as a potential predictor (Lee 
et  al. 2016; Etienne et  al. 2017). The ENEST1st study 
evaluated deep molecular response with frontline nilotinib, 
which potentially indicates that the population may be eli-
gible to attempt TFR. The impact on age, if any, on attain-
ing deep molecular response may indicate potential differ-
ences in the age of the population, which can attempt TFR. 
However, since no significant differences were observed in 
the response rates with the different age groups, an impact 
of age on the patients attempting TFR or on the outcome 
of TFR may not be likely. This is further indicated in the 
studies, in which age was not found to be a predictor for 
outcomes of TFR (Lee et al. 2016).
Overall, safety was consistent with the known profile of 
nilotinib. The overall safety signals for the ENEST1st study 
were similar to those of the ENESTnd, though at a lower 
frequency than ENESTnd suggesting better management of 
the disease in this study (Hochhaus et al. 2016a). Although 
the distribution of some of the AEs differed across age 
groups, safety signals specific for a particular age group 
could not be identified except for CVEs, which were sig-
nificantly less for the young patients. These data highlight 
the need for appropriate monitoring for relevant risk factors 
in all patients receiving nilotinib therapy with immediate 
appropriate intervention when needed, especially if a CVE 
occurs. (Rea et al. 2015; Castagnetti et al. 2016).
Even though the study enrolled a large patient popula-
tion with sufficient number of patients in each group, the 
subanalysis was not designed to formally test the difference 
across the subgroups. In the ENEST1st study, monitoring 
of glucose and lipid was not mandatory and the overall fre-
quency of these AEs and also their differences with age, if 
any, could not be ascertained and were probably underes-
timated. The current classification used in the study does 
not conform to any standard classification of age, e.g., the 
US census bureau or World Health Organization, and was 
done to introduce additional categories, though arbitrarily, 
to identify differences in population if any.
The ENEST1st study had shown high molecular 
response rates with approximately 55.2% of the patients 
achieving  MR4 by 24 months. This subanalysis of the 
ENEST1st study showed that age had minimal impact on 
the deep molecular response rates associated with nilotinib 
therapy in newly diagnosed patients with CML and eventu-
ally on the eligibility of the patients to attempt TFR. This 
together with almost 100% freedom from progression by 
24 months in any of the age groups further demonstrated 
the efficacy of frontline nilotinib. Although the main causes 
of discontinuation were similar across the young, mid-
dle-aged, elderly, and old patients, the distribution varied 
slightly across the age groups. Understanding the varia-
tions in disease characteristics and AEs with TKI therapy 
with respect to patient age may help improve CML therapy. 
Especially in older patients with a higher proportion of 
comorbidities, a more flexible dosing scheme may be war-
ranted to increase tolerability while maintaining the deep 
molecular responses.
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